Creative Commons source reading · Performance analysis and forecasting
Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review
Sandro La Vignera; Rosita A. Condorelli
Originally published in Int J Mol Sci · 2026-07-08
From the article
Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.
Abstract
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have revolutionized the management of type 2 diabetes and obesity. Recent evidence suggests these agents may influence athletic performance through effects on body composition, energy metabolism, and cardiovascular function. This narrative review critically evaluates whether incretin therapies could constitute doping under World Anti-Doping Agency (WADA) criteria. We narratively reviewed the literature on incretin pharmacology, metabolic effects relevant to athletic performance, and anti-doping regulations, searching PubMed, Scopus, and Web of Science using terms including “GLP-1 receptor agonists”, “DPP-4 inhibitors”, “doping”, “athletic performance”, “WADA”, and “sports pharmacology”, without date…
8. Discussion
This narrative review has comprehensively evaluated the available evidence regarding incretin-based therapies and their potential classification as doping agents in sports. The analysis reveals a complex landscape where theoretical performance-enhancing mechanisms exist, but clinical evidence of meaningful performance benefits in athletes is lacking [5].
8.1. Summary of Key Findings
Molecular and Metabolic Effects: GLP-1 RAs exert pleiotropic effects through GLP-1R activation, including enhanced insulin secretion, appetite suppression, weight loss, cardiovascular protection, and anti-inflammatory actions [3]. Preclinical studies demonstrate that GLP-1R signaling enhances exercise endurance, promotes oxidative muscle fiber transformation, augments mitochondrial biogenesis, and improves glucose uptake through AMPK-dependent pathways [6]. These molecular mechanisms provide a theoretical basis for performance enhancement, particularly in endurance sports. Body Composition Effects: GLP-1 RAs induce substantial weight loss (15–22.5% with current agents) predominantly from fat mass, with preferential reduction in visceral adipose tissue [2]. However, 20–30% of weight loss comprises lean mass, raising concerns about…
Editorial reading guide
- How did the authors define training exposure and performance response?
- What alternative explanations, confounders or individual differences limit the conclusion?
